CVRx（CVRX）株式概要
CVRx, Inc.は商業段階の医療機器会社であり、米国、ドイツ、および国際的な心臓血管疾患患者向けの神経調節ソリューションの開発、製造、商業化に従事している。 詳細
CVRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CVRx, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$5.60 |
| 52週高値 | US$11.30 |
| 52週安値 | US$4.37 |
| ベータ | 0.78 |
| 1ヶ月の変化 | 4.09% |
| 3ヶ月変化 | -33.09% |
| 1年変化 | -15.02% |
| 3年間の変化 | -58.70% |
| 5年間の変化 | -72.14% |
| IPOからの変化 | -80.00% |
最新ニュース
ナラティブの更新 • Jun 16
CVRX: BENEFIT-HF Trial Momentum And Steady Guidance Will Support Bullish Stock Outlook
Analysts have nudged their price target on CVRx slightly higher to $6.00, reflecting modest adjustments to key valuation inputs such as the discount rate, revenue growth expectations, profit margin assumptions, and the forward P/E multiple. What’s in the News for CVRx CVRx began enrollment in the BENEFIT-HF trial, described as one of the largest therapeutic cardiac device studies in heart failure, targeting 2,500 patients across about 150 centers in the U.S. and Germany, with support from CMS Category B IDE coverage.ナラティブの更新 • Jun 02
CVRX: Trial Progress And Steady Guidance Will Likely Cap Near Term Upside Potential
Analysts have modestly adjusted their price target on CVRx, reflecting updated assumptions around fair value at 6.0, a discount rate of 8.35%, revenue growth of 15.41%, profit margin of 12.19%, and a future P/E of 18.62. They are using these revised inputs to fine tune expectations rather than signal a major shift in outlook.分析記事 • May 15
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders in CVRx, Inc. ( NASDAQ:CVRX ) had a terrible week, as shares crashed 22% to US$5.74 in the week since its...Recent updates
ナラティブの更新 • Jun 16
CVRX: BENEFIT-HF Trial Momentum And Steady Guidance Will Support Bullish Stock Outlook
Analysts have nudged their price target on CVRx slightly higher to $6.00, reflecting modest adjustments to key valuation inputs such as the discount rate, revenue growth expectations, profit margin assumptions, and the forward P/E multiple. What’s in the News for CVRx CVRx began enrollment in the BENEFIT-HF trial, described as one of the largest therapeutic cardiac device studies in heart failure, targeting 2,500 patients across about 150 centers in the U.S. and Germany, with support from CMS Category B IDE coverage.ナラティブの更新 • Jun 02
CVRX: Trial Progress And Steady Guidance Will Likely Cap Near Term Upside Potential
Analysts have modestly adjusted their price target on CVRx, reflecting updated assumptions around fair value at 6.0, a discount rate of 8.35%, revenue growth of 15.41%, profit margin of 12.19%, and a future P/E of 18.62. They are using these revised inputs to fine tune expectations rather than signal a major shift in outlook.分析記事 • May 15
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders in CVRx, Inc. ( NASDAQ:CVRX ) had a terrible week, as shares crashed 22% to US$5.74 in the week since its...ナラティブの更新 • May 05
CVRX: Reduced Multiple Expectations Will Likely Constrain Future Share Price Upside
Analysts have reduced their average CVRx price target by $1 to reflect updated views on the company’s risk profile, growth trajectory, profitability expectations, and likely P/E multiple, while keeping fair value broadly in line with prior estimates. Analyst Commentary Recent Street research on CVRx points to a more cautious tone, with the headline takeaways centered on slightly lower price targets and an increased focus on execution and valuation risks.ナラティブの更新 • Apr 19
CVRX: Execution Risks And Updated Assumptions Will Likely Restrain Upside
Analysts have trimmed their price targets on CVRx by $1, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research notes, including one from JPMorgan, point to a more cautious stance on CVRx, reflected in the $1 price target trims.ナラティブの更新 • Mar 31
CVRX: Execution Risks And Recent Price Cuts Will Likely Limit Upside
Analysts have trimmed their CVRx price targets by $1 to reflect updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations, while maintaining their fair value estimate at $6.00. Analyst Commentary Recent Street research, including updated work from JPMorgan, reflects a more cautious stance on CVRx even as the published fair value estimate remains at $6.00.ナラティブの更新 • Mar 16
CVRX: Execution Risks Around Profitability Path Will Likely Cap Future Upside
Analysts have trimmed their CVRx price targets by $1 to $6, reflecting updated assumptions around revenue growth, discount rate, profit margins, and future P/E expectations. Analyst Commentary Recent research updates point to a more cautious stance on CVRx, with both JPMorgan and other bearish analysts trimming price targets by $1.ナラティブの更新 • Mar 01
CVRX: Reimbursement Progress Will Face Cautious Outlook On Profitability Path
Analysts have trimmed their price target on CVRx by $1, reflecting updated assumptions around discount rates, revenue growth, profit margins and forward P/E that still align with recent Street research from firms that reduced their targets by a similar amount. Analyst Commentary Street research on CVRx has recently centered on slightly lower price targets, including a US$1 trim from JPMorgan, which aligns with similar reductions from other bearish analysts.分析記事 • Feb 15
Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results
One of the biggest stories of last week was how CVRx, Inc. ( NASDAQ:CVRX ) shares plunged 24% in the week since its...ナラティブの更新 • Feb 15
CVRX: Reimbursement Shift And BENEFIT-HF Trial Will Reshape Long-Term Upside
Analysts have trimmed their CVRx price targets by $1, reflecting updated fair value estimates and assumptions on growth, profitability, and future P/E multiples, while maintaining a constructive view on the story. Analyst Commentary Recent Street research includes price target trims of $1 from both JPMorgan and other bearish analysts, which reflect a more cautious stance on CVRx's risk and reward profile.分析記事 • Dec 30
CVRx, Inc.'s (NASDAQ:CVRX) Popularity With Investors Under Threat As Stock Sinks 26%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Nov 08
CVRx, Inc. (NASDAQ:CVRX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$11.50
CVRx, Inc. ( NASDAQ:CVRX ) just released its quarterly report and things are looking bullish. CVRx beat expectations...分析記事 • Oct 16
After Leaping 39% CVRx, Inc. (NASDAQ:CVRX) Shares Are Not Flying Under The Radar
CVRx, Inc. ( NASDAQ:CVRX ) shares have had a really impressive month, gaining 39% after a shaky period beforehand...分析記事 • Sep 16
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 08
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Second-Quarter Report
It's been a sad week for CVRx, Inc. ( NASDAQ:CVRX ), who've watched their investment drop 13% to US$6.94 in the week...分析記事 • Jul 15
CVRx, Inc.'s (NASDAQ:CVRX) P/S Is Still On The Mark Following 25% Share Price Bounce
CVRx, Inc. ( NASDAQ:CVRX ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Jul 02
CVRx: Sell-Off Ignores Its True Potential
Summary CVRx offers a unique, FDA-approved heart failure therapy with Medicare reimbursement, positioning it for significant market adoption and growth. The recent share price drop is an overreaction to sales force restructuring and reimbursement fears, while earnings and revenue estimates remain stable. Current valuation is deeply discounted versus sector peers, despite high-teens revenue growth and clear operating leverage potential as sales ramp up. Management insider buying and a net cash balance sheet reinforce my conviction that CVRX is a speculative Buy at these levels. Read the full article on Seeking Alpha分析記事 • Jun 14
Is CVRx (NASDAQ:CVRX) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • May 09
Investors Appear Satisfied With CVRx, Inc.'s (NASDAQ:CVRX) Prospects As Shares Rocket 25%
Those holding CVRx, Inc. ( NASDAQ:CVRX ) shares would be relieved that the share price has rebounded 25% in the last...Seeking Alpha • Apr 09
CVRx, Inc.: Overreaction Creates Buying Opportunity
Summary CVRx, Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness. CVRX shares are a buy with a price target of $10. Read the full article on Seeking Alpha
新しいナラティブ • Mar 29
Expanding 48 US Territories And New Codes Will Broaden Access
Expansion in US territories and implanting centers is expected to drive significant revenue growth and market penetration.分析記事 • Mar 07
With A 29% Price Drop For CVRx, Inc. (NASDAQ:CVRX) You'll Still Get What You Pay For
CVRx, Inc. ( NASDAQ:CVRX ) shares have had a horrible month, losing 29% after a relatively good period beforehand...分析記事 • Jan 16
Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 27%
Despite an already strong run, CVRx, Inc. ( NASDAQ:CVRX ) shares have been powering on, with a gain of 27% in the last...分析記事 • Dec 26
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Nov 07
CVRx: Impressive Top-Line Growth Seems Priced In
Summary CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution. CVRX is a hold with a price target of $14. Read the full article on Seeking Alpha分析記事 • Nov 01
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report
The investors in CVRx, Inc. 's ( NASDAQ:CVRX ) will be rubbing their hands together with glee today, after the share...分析記事 • Oct 10
Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX)
When you see that almost half of the companies in the Medical Equipment industry in the United States have...分析記事 • Jul 31
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Jun 18
Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge
Those holding CVRx, Inc. ( NASDAQ:CVRX ) shares would be relieved that the share price has rebounded 32% in the last...分析記事 • May 04
The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%
To the annoyance of some shareholders, CVRx, Inc. ( NASDAQ:CVRX ) shares are down a considerable 47% in the last month...分析記事 • Apr 10
Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Feb 29
The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders won't be pleased to see that the share price has had a very rough month...株主還元
| CVRX | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -5.7% | 2.2% | 1.6% |
| 1Y | -15.0% | -19.0% | 18.6% |
業界別リターン: CVRX過去 1 年間で-19 % の収益を上げたUS Medical Equipment業界を上回りました。
リターン対市場: CVRXは、過去 1 年間で18.6 % のリターンを上げたUS市場を下回りました。
価格変動
| CVRX volatility | |
|---|---|
| CVRX Average Weekly Movement | 12.8% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: CVRXの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: CVRXの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2000 | 223 | Kevin Hykes | www.cvrx.com |
CVRx, Inc.は、商業段階の医療機器企業であり、米国、ドイツ、および国際的な心血管疾患患者向けの神経調節ソリューションの開発、製造、商業化に従事している。同社は、頸動脈の壁にある圧受容器に電気パルスを供給し、圧受容器シグナルの低下に対抗する植え込み型デバイスであるバロスチムを提供しており、また、循環器系を自律神経系にリンクさせる圧反射活性化療法を提供している。同社は直販部隊、販売代理店、独立代理店を通じて製品を販売している。同社は2000年に法人化され、ミネソタ州ミネアポリスに本社を置いている。
CVRx, Inc. 基礎のまとめ
| CVRX 基礎統計学 | |
|---|---|
| 時価総額 | US$148.60m |
| 収益（TTM） | -US$52.66m |
| 売上高(TTM) | US$59.07m |
2.5x
P/Sレシオ-2.8x
PER（株価収益率CVRX は割高か？
公正価値と評価分析を参照収益と収入
| CVRX 損益計算書（TTM） | |
|---|---|
| 収益 | US$59.07m |
| 売上原価 | US$8.16m |
| 売上総利益 | US$50.91m |
| その他の費用 | US$103.57m |
| 収益 | -US$52.66m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.98 |
| グロス・マージン | 86.18% |
| 純利益率 | -89.15% |
| 有利子負債／自己資本比率 | 200.9% |
CVRX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/06 11:55 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
CVRx, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| William Plovanic | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Sarah James | Cantor Fitzgerald & Co. |